News

Solid IO Awarded €400 000 R&D Grant From Business Finland

May 8, 2025

This significant early-stage public funding strengthens our position as a developer of next-generation precision oncology diagnostics and enables us to accelerate our path toward market entry.

TAGS:
Grant
Cancer care

Solid IO has been awarded €400 000 research and development grant from Business Finland. This significant early-stage public funding strengthens our position as a developer of next-generation precision oncology diagnostics and enables us to accelerate our path toward market entry.

Solid IO is developing a human-based diagnostic technology that mimics an individual patient’s biological response to help physicians predict how their cancer will respond to specific treatments. This brings greater accuracy and predictability to treatment decisions in immuno-oncology, where uncertainty still often plays a role today.

In recent months, both the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) have emphasized the need to shift biomedical research and development away from animal and cell-line models and toward human biology-based approaches. While this shift is especially relevant in drug development, it reflects a broader global move toward more precise, patient-centric solutions. Solid IO is translating that shift into practical, clinical application.

"The grant awarded to Solid IO reflects our significant international potential. It also demonstrates that the Finnish innovation ecosystem recognizes the need for new approaches in diagnostics and supports solutions with the potential to impact healthcare systems and public health globally. We are grateful for Business Finland’s trust and proud to build human-based diagnostics as part of a nationally recognized development priority. I’m also personally delighted that this grant brings us to our €1.2 M pre-seed funding target."
– Noora Hujala, CEO, Solid IO

"Solid IO’s project represents the kind of high-quality, science-based innovation that Business Finland is committed to supporting on the path to commercialization. The company has clear international growth potential and a concrete path toward market entry."
– Eija-Riitta Hämäläinen, Senior Advisor, Business Finland

Business Finland is a public organization under the Finnish Ministry of Employment and the Economy and the leading accelerator of global growth in Finland. It creates the conditions for new growth by funding research and innovation and by supporting internationalization.

Learn more about recent global developments in human-based technologies:

FDA Announces Plan toPhase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

NIH to prioritizehuman-based research technologies 

 

 

 

 

Shape the future of cancer care

Join us in transforming cancer care with groundbreaking organ-on-chip technology. We’re calling on researchers, clinicians, and investors to partner with us in advancing precision medicine, accelerating innovation, and expanding global access to personalized oncology. Together, we can bring clarity and better outcomes to cancer care worldwide.

Contact us